Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Sept. 22 — Purdue Pharma LP and AnaBios Corp. Sept. 22 said they intend to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel drug compounds for the treatment of chronic pain.
The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X technology, the companies said.
The Phase-X technology enables the discovery of novel drugs directly in human tissues, bypassing animal experimentation, the companies said. AnaBios generates highly valuable and predictive human data that ensure the selection of the most effective and safest drugs before investing in expensive and time consuming clinical trials, they said.
“The prospect of combining AnaBios’ unique platform and Purdue Pharma’s top quality chemistry exemplifies the powerful nexus of technology-based discovery and industry collaboration,” Mark Timney, president and chief executive officer of Purdue Pharma, said. “This creative partnership fits in well with our strategic plan to continue development of our existing therapeutic programs and ultimately bring value to patients suffering from pain and to healthcare providers.”
Purdue Pharma is based in Stamford, Conn. and AnaBios is based in San Diego.
Notify me when updates are available (No standing order will be created).
Put me on standing order
Notify me when new releases are available (no standing order will be created)